PUBLICATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Publications
2000 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
No.75
Cell metab.,
“MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity” (Cell Metab., DOI: 10.1016/j.cmet.2022.10.007., 2022)
VIEW ARTICLE 
No.74
Cell Death & Disease.,
“Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH” (Cell Death & Disease., DOI: 10.1038/s41419-022-05452-x., 2022)
VIEW ARTICLE
No.74
bioRxiv.,
“Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG)” (bioRxiv., DOI: https://doi.org/10.1101/2022.11.17.516628, 2022)
VIEW ARTICLE
No.72
J Clin Exp Hepatol.,
“Hepatoprotective effects of Aureobasidium pullulans derived β 1,3-1,6 glucans in a murine model of non-alcoholic steatohepatitis - Journal of Clinical and Experimental Hepatology” (J Clin Exp Hepatol., DOI:https://doi.org/10.1016/j.jceh.2022.06.008., 2022)
VIEW ARTICLE
No.71
Cell metab.,
“Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia” (Cell Metab. DOI: 10.1016/j.cmet.2022.05.004., 2022)
VIEW ARTICLE
No.70
PLoS One.,
“A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE
No.69
PLoS One.,
“Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model”(PLoS One., DOI: 10.1371/journal.pone.0261310., 2022)
VIEW ARTICLE
No.68
Cells.,
“Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non Alcoholic Steatohepatitis” (Cells., DOI: 10.3390/cells11040720., 2022)
VIEW ARTICLE
No.67
PLoS One.,
“Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosisbut not NASH progression” (PLoS One., DOI: 10.1371/journal.pone.0263828., 2022)
VIEW ARTICLE
No.66
Mol Metab.,
“Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function” (Mol Metab., doi: 10.1016/j.molmet.2022.101487., 2022)
VIEW ARTICLE
No.65
Transl Oncol Clin Exp Hepatol.,
“Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments” (Transl Oncol., DOI: 10.1016/j.tranon.2021.101201., 2021)
VIEW ARTICLE
No.64
Surgery Open Science.,
“In vivo diffuse reflectance spectroscopic analysis of fatty liver with I inflammation in mice” (Surg Open Sci., DOI: 10.1016/j.sopen.2021.07.002., 2021)
VIEW ARTICLE
No.63
Cell Mol Gastroenterol Hepatol.,
"Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice" (Cell Mol Gastroenterol Hepatol. DOI: 10.1016/j.jcmgh.2020.10.010., 2020)
VIEW ARTICLE
No.62
Journal of Lipid Research.,
“Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition” (J Clin Exp Gastroenterol., DOI: 10.1194/jlr.RA120000924., 2020)
VIEW ARTICLE
No.61
Clinical and Experimental Gastroenterology.,
“Changes in Function and Dynamics in Hepatic and Splenic Macrophages in Non-Alcoholic Fatty Liver Disease” (Clin Exp Gastroenterol., DOI: 10.2147/CEG.S248635., 2020)
VIEW ARTICLE
No.60
Purinergic Signalling,
“Design and in vivo activity of A3 adenosine receptor agonist prodrugs” (Purinergic Signal., DOI: 10.1007/s11302-020-09715-0., 2020)
VIEW ARTICLE
No.59
Cell Reports Medicine,
“Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis” (Cell Rep Med ., DOI: DOI: 10.1016/j.xcrm.2020.100056., 2020)
VIEW ARTICLE
No.58
Journal of Biochemical and Molecular Toxicology,
“Omaveloxolone and TX63682 Are Hepatoprotective in the STAM™ Mouse Model of Nonalcoholic Steatohepatitis” (J Biochem Mol Toxicol., DOI: 10.1002/jbt.22526., 2020)
VIEW ARTICLE
No.57
Journal of Medicinal Chemistry,
“6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis” (J Med Chem., DOI: 10.1021/acs.jmedchem.0c00542., 2020)
VIEW ARTICLE
No.56
Scientific Reports,
“Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice” (Sci Rep., DOI: 10.1038/s41598-020-64293-w)
VIEW ARTICLE
No.55
Journal of Medicinal Chemistry,
“[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis” (J Med Chem., DOI: 10.1021/acs.jmedchem.9b01440., 2020)
VIEW ARTICLE
No.54
Diabetology & Metabolic Syndrome,
“Intracellular toxic advanced glycation end-products (TAGE) in myoblasts may cause sarcopenia: Research article of a non-clinical study” (Diabetol. Metab. Syndr., DOI: 10.21203/rs.2.23269/v1, 2020)
VIEW ARTICLE
No.53
European Radiology Experimental,
“Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH)” (Eur Radiol Exp., 4: 3., 2020)
VIEW ARTICLE
No.52
Journal of medicinal chemistry,
“Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.” (J Med Chem., DOI: 10.1021/acs.jmedchem.9b01621., 2020)
VIEW ARTICLE
No.51
Expert Opinion on Investigational Drugs,
“Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.” (Expert Opin Investig Drugs. 3:1-9., 2020)
VIEW ARTICLE
No.50
JHEP Reports,
“A Blocking Monoclonal Antibody to CCL24 Alleviates Liver Fibrosis and Inflammation in Experimental Models for Liver Damage” (JHEP Reports, 10.1016/j.jhepr.2019.100064, 2020)
VIEW ARTICLE
No.49
International Journal of Molecular Medicine,
“The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.” (Int J Mol Med, 44(6):2256-2264, 2019)
VIEW ARTICLE
No.48
Science Translational Medicine,
“Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” (Sci Transl Med., 11(520), 2019)
VIEW ARTICLE
No.47
Cells,
“Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis” (Cells, 8;8(11), 2019)
VIEW ARTICLE
No.46
International Journal of Molecular Sciences,
“The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”(Int. J. Mol. Sci. , 20(20), 5237, 2019)
VIEW ARTICLE
No.45
Toxicological Sciences,
“Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.”(Toxicol Sci., 170(2):273-282, 2019)
VIEW ARTICLE
No.44
Biochemistry,
“A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease” (Biochemistry, 58(37):3911-3917, 2019)
VIEW ARTICLE
No.43
Hepatology Communications,
“Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents“ (Hepatol Commun., 3(8): 1085–1097, 2019)
VIEW ARTICLE
No.42
International Journal of Gastroenterology,
"Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis" (International Journal of Gastroenterology, DOI: 10.11648/j.ijg.20190301.12, 2019)
VIEW ARTICLE
No.41
Experimental Animals,
"Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice" (Exp Anim., DOI: 10.1538/expanim.18-0152, 2019)
VIEW ARTICLE
No.40
Frontiers in Genetics,
"Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis" (Front Genet., May 29;10:486, 2019)
VIEW ARTICLE
No.39
Journal of Cellular and Molecular Medicine,
"The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis" (J Cell Mol Med., 23:1759-1770, 2019)
VIEW ARTICLE
No.38
Scientific Reports,
"Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan" (Sci Rep., Mar 8;9(1):4003, 2019)
VIEW ARTICLE
No.37
NPJ Precision Oncology,
"Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology" (NPJ Precis Oncol., DOI: 10.1038/s41698-018-0068-8, 2018)
VIEW ARTICLE
No.36
Cellular and Molecular Gastroenterology and Hepatology,
"Dipeptidyl Peptidase 4 inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice" (CMGH, DOI: 10.1016/j.jcmgh.2018.08.008, 2018)
VIEW ARTICLE
No.35
Glycoconjugate Journal,
“Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM™ mice” (Glycoconj J., Oct;35(5):467-476, 2018)
VIEW ARTICLE
No.34
Proc Natl Acad Sci U S A,
“Integrative genomic analysis of mouse and human hepatocellular carcinoma” (Proc Natl Acad Sci U S A, DOI: 10.1073/pnas.1811029115, 2018)
VIEW ARTICLE
No.33
Liver Cancer,
“Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model” (Liver Cancer, DOI: 10.1159/000491763, 2018)
VIEW ARTICLE
No.32
PLoS One,
“Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH” (PLoS One, 13(5): e0194568 , 2018)
VIEW ARTICLE
No.31
World Journal of Gastroenterology,
“Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma” (World J Gastroenterol, 24(18):1989-1994, 2018)
VIEW ARTICLE
No.30
The FASEB Journal,
“Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma“ (FASEB J, DOI:10.1096/fj.201700866R, 2017)
VIEW ARTICLE
No.29
Oncotarget,
“MicroRNA deregulation in nonalcoholic steatohepatitisassociated liver carcinogenesis” (Oncotarget, 8:88517-88528, 2017)
VIEW ARTICLE
No.28
Oncotarget,
“Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet” (Oncotarget, 8:39978-39993, 2017)
VIEW ARTICLE
No.27
Physiological Research,
“Pathophysiological analysis of the progression of hepatic lesions in STAM™ mice.” (Physiological Research, 66:791-799, 2017)
VIEW ARTICLE
No.26
Molecular Cancer Research,
“Inhibition of the cell death pathway in non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation” (Molecular Cancer Research, DOI:10.1158/1541-7786.MCR-17-0109, 2017)
VIEW ARTICLE
No.25
Magnetic Resonance Imaging,
“The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.” (Magn Reson Imaging, 38:123-128, 2017)
VIEW ARTICLE
No.24
Journal of Pharmacology and Experimental Therapeutics,
“Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis” (J Pharmacol Exp Ther, 360:1-13, 2017)
VIEW ARTICLE
No.23
Oncotarget,
“Distinctly altered gut microbiota in the progression of liver disease” (Oncotarget, 7: 19355-19366, 2016)
VIEW ARTICLE
No.22
Diabetology & Metabolic Syndrome,
“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes“ (Diabetology & Metabolic Syndrome, 8:45, 2016)
VIEW ARTICLE
No.21
Journal of Immunology, Infection & Inflammatory Diseases,
“Solithromycin Diminishes Steatohepatitis by Modulating Gluconeogenesis and Inhibits Tumor Growth in a Diabetic Mouse Model of Non-Alcoholic Steatohepatitis” (J Immunol Infect Inflam Dis, 1:004, 2016)
VIEW ARTICLE
No.20
PLoS One,
“Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis“ (PLoS One, 11:e0158156, 2016)
VIEW ARTICLE
No.19
Cell Reports,
“Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling” (Cell Press, 15:1175-1189, 2016)
VIEW ARTICLE
No.18
International Journal of Medical Sciences,
“Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease” (Int. J. Med. Sci, 13:169-178, 2016)
VIEW ARTICLE
No.17
European Journal of Pharmacology,
“Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model” (Eur J Pharmacol, 772:22-32, 2016)
VIEW ARTICLE
No.16
Scientific Reports,
“Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis” (Sci Rep., 12466, 2015)
VIEW ARTICLE
No.15
International Journal of Obesity,
“Low cytochrome oxidase 4I1 links mitochondriazzzl dysfunction to obesity and type 2 diabetes in humans and mice” (Int J Obes, 39:1254-63, 2015)
VIEW ARTICLE
No.14
Proc Natl Acad Sci U S A,
“Immunomodulatory spherical nucleic acids” (Proc Natl Acad Sci U S A, 31;112:3892-7, 2015)
VIEW ARTICLE
No.13
Oncology Reports,
“Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis” (Oncol Rep, 33:1657-66, 2015)
VIEW ARTICLE
No.12
Drug R D,
“In Vivo Efficacy Study of Milk Thistle Extract (ETHIS-094TM) in STAM™ Model of Nonalcoholic Steatohepatitis” (Drugs R D, 14:291-9, 2014)
VIEW ARTICLE
No.11
PLoS One,
“Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging” (PLoS One, 9:e112667, 2014)
VIEW ARTICLE
No.10
Cancer Science,
“Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis” (Cancer Sci, 105:1254-60, 2014)
VIEW ARTICLE
No.9
Anticancer Research,
“Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice” (Anticancer Res, 34:4849-4856, 2014)
VIEW ARTICLE
No.8
PLoS One,
“L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.” (PLoS One, 9:e100627, 2014)
VIEW ARTICLE
No.7
Medical Molecular Morphology,
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis” (Med Mol Morph, 47:137-149)
VIEW ARTICLE
No.6
PLoS One,
“Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors” (PLoS One, 8:e83481, 2013)
VIEW ARTICLE
No.5
International Journal of Oncology,
“Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide” (Int J Oncol, 42:831-838, 2013)
VIEW ARTICLE
No.4
International Journal of Experimental Pathology,
“Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice” (Int J Exp Pathol, 94: 217-225, 2013)
VIEW ARTICLE
No.3
Medical Molecular Morphology,
“A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma” (Med Mol Morph, 46:141-152, 2013)
VIEW ARTICLE
No.2
Hepatology,
“Hydrogen-rich water prevents progression of non-alcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice” (Hepatology, 56:912-921, 2012)
VIEW ARTICLE
No.1
Journal of Nutritional Science and Vitaminology,
“Effects of Dietary Supplementation with Betaine on a Nonalcoholic Steatohepatitis (NASH) Mouse Model” (J Nutr Sci Vitaminol, 58:371–375, 2012)
VIEW ARTICLE
test
testtesttesttest
VIEW ARTICLE